Patents by Inventor Wataru Akahata

Wataru Akahata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED VACCINE DESIGN DEVELOPMENTS
    Publication number: 20230391833
    Abstract: Provided herein is an isolated polynucleotide, which encodes a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally to ferritin. Also provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally to ferritin. The antigen may be influenza. The polynucleotide such as RNA is useful as a vaccine against influenza infection.
    Type: Application
    Filed: May 30, 2023
    Publication date: December 7, 2023
    Applicant: VLP Therapeutics Japan, INC.
    Inventor: Wataru AKAHATA
  • TREATMENT OF INFLAMMATORY CONDITIONS
    Publication number: 20230330209
    Abstract: The present disclosure provides a method for treating an inflammatory condition, especially an age related inflammatory condition in a mammalian subject in need thereof, which comprises an effective amount of a virus like particle comprising a viral structural protein and a galectin-3 antigen, a composition or vaccine comprising for the purpose thereof.
    Type: Application
    Filed: April 17, 2023
    Publication date: October 19, 2023
    Applicants: CYN-K, LLC, Kyoto University
    Inventors: Ryuji Ueno, Wataru Akahata, Kazuya Goto
  • VIRUS-LIKE PARTICLES AND METHODS OF USE
    Publication number: 20230295242
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Application
    Filed: June 7, 2023
    Publication date: September 21, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
  • Virus-like particles and methods of use
    Patent number: 11718647
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: August 8, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
  • EFFICIENT VACCINE
    Publication number: 20230201333
    Abstract: Provided herein is an isolated polynucleotide, which encodes structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising an antigenic protein fused to a signal sequence, a transmembrane domain and at least one peptide selected from CD4+ T cell epitopes and CD8+ T cell epitopes. The polynucleotide is useful for manufacturing a vaccine against virus infection, especially, COVID-19 infection, the treatment of a cancer and/or an inflammatory disease.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 29, 2023
    Applicant: VLP Therapeutics Japan, LLC
    Inventors: Wataru AKAHATA, Jonathan F. SMITH, Jeffery Leo ALEXANDER, Takashi SEKIDA
  • VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE
    Publication number: 20230025038
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Application
    Filed: June 27, 2022
    Publication date: January 26, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
  • GALECTIN-TARGETING IMMUNOTHERAPY
    Publication number: 20220347261
    Abstract: The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.
    Type: Application
    Filed: April 22, 2022
    Publication date: November 3, 2022
    Applicant: VLP Therapeutics, Inc.
    Inventor: Wataru AKAHATA
  • Treatment method utilizing chikungunya virus (CHIKV) virus-like particles (VLPS) comprising the C, E2 and E1 structural proteins
    Patent number: 11369674
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: June 28, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
  • Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
    Patent number: 11345726
    Abstract: The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: May 31, 2022
    Assignee: VLP Theranentics. Inc.
    Inventors: Ryuji Ueno, Wataru Akahata
  • ALPHAVIRUS REPLICON PARTICLE
    Publication number: 20220002682
    Abstract: Provided is an alphavirus replicon particle (ARP), which comprises (i) alphavirus structural proteins comprising capsid and/or envelope, and (ii) an alphavirus replicon comprising a polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and at least one gene of interest wherein at least one of capsid, and E3 and E2 in the envelope comprise one or more amino acid alteration but E1 in the envelope comprises no amino acid alteration.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 6, 2022
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Ryuji UENO
  • VIRUS-LIKE PARTICLES AND METHODS OF USE
    Publication number: 20210388034
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Application
    Filed: August 24, 2021
    Publication date: December 16, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
  • CYTOKINE IMMUNOTHERAPY
    Publication number: 20210340567
    Abstract: Provided herein is a novel immunologically-active alphavirus replicon vector which comprises a nucleic acid encoding alphavirus nonstructural proteins nsp1-4 and a cytokine protein(s)/polypeptide(s), which is useful for the treatment of a cancer and/or an inflammatory disease.
    Type: Application
    Filed: April 28, 2021
    Publication date: November 4, 2021
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Jonathan F. SMITH
  • CORONAVIRUS VACCINE
    Publication number: 20210322541
    Abstract: Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 21, 2021
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Jonathan F. SMITH, Ryuji UENO
  • Virus-like particles and methods of use
    Patent number: 11098084
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: August 24, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
  • Virus Like Particle Compositions and Methods of Use
    Publication number: 20200085938
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Application
    Filed: July 23, 2019
    Publication date: March 19, 2020
    Inventors: Gary J. NABEL, Wataru AKAHATA, Srinivas RAO
  • MALARIA VACCINE
    Publication number: 20190351041
    Abstract: The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections.
    Type: Application
    Filed: March 28, 2019
    Publication date: November 21, 2019
    Applicant: VLP Therapeutics, LLC
    Inventors: Ryuji UENO, Wataru AKAHATA
  • Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
    Patent number: 10464986
    Abstract: The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 5, 2019
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Virus like particle comprising modified envelope protein E3
    Patent number: 10385101
    Abstract: A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 20, 2019
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Methods for the induction of immune responses in a subject compromising administering virus-like particles (VLPS) prepared from Chikungunya virus structural proteins
    Patent number: 10369208
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: August 6, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
  • ALPHAVIRUS REPLICON PARTICLE
    Publication number: 20190185822
    Abstract: Provided is an alphavirus replicon particle (ARP), which comprises (i) alphavirus structural proteins comprising capsid and/or envelope, and (ii) an alphavirus replicon comprising a polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and at least one gene of interest wherein at least one of capsid, and E3 and E2 in the envelope comprise one or more amino acid alteration but E1 in the envelope comprises no amino acid alteration.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 20, 2019
    Applicant: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno